Document is current
Any future updates will be listed below
-
Authors
Rennie, Anna
Nemy, Milan
Jerele, Cene
Rodríguez-Baz, Iñigo
Montal, Victor
Bejanin, Alexandre
Kramberger, Milica G
Aarsland, Dag
Fortea, Juan
Lleó, Alberto
Westman, Eric
Alcolea, Daniel
Ferreira, Daniel
-
Funding
Funding for this research was provided by:
Swedish Research Council (2022-00916, 2022-00916)
- License Information
-
More Information
Article History
Received: 5 June 2025
Accepted: 8 August 2025
First Online: 21 August 2025
Competing interests
: D.Aa. has received research support and/or honoraria from AstraZeneca, H. Lundbeck, Novartis Pharmaceuticals and GE Health and served as a paid consultant for H. Lundbeck, Eisai and Evonik. D.Al. participated in advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A., and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U., Neuraxpharm, Alter Medica, Lilly and Esteve Pharmaceuticals S.A. D.Al. declares a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease). D.F. consults for BioArctic and has received honoraria from Esteve.
